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1. Introduction
An estimated 400 million people are chronically infected with hepatitis B virus (HBV),
worldwide, and over 500,000 chronic hepatitis B (CHB) patients die annually because of
cirrhosis and hepatocellular carcinoma (HCC) [1,2]. Clinical care for patients with CHB has
advanced considerably during the last decades as a result of growing knowledge about the
mechanisms of disease, diagnostic procedures and advances in therapeutic options.
Since the introduction of interferon alpha as first antiviral therapy at the end of the 1980s,
management of CHB has dramatically evolved due to the availability of direct antivirals which
greatly increased the therapeutic options, thus permitting treatment of patients previously
excluded from IFN treatment. In particular, new oral antivirals have been developed and used
in clinical practice, leading to a substantial improvement in antiviral efficacy, mainly due to
their increased potency and higher barrier to resistance. On the other hand, the expanding
molecular and clinical knowledge of HBV infection and evolution of therapy have made the
management of CHB patients much more complex. Therefore, within the recent past, several
guidelines have been issued by many organizations and professional expert panels in order
to better define diagnostic criteria and improve therapeutic decisions.
This chapter focuses on the current management of chronic hepatitis B patients and reviews
up-to-date studies and concepts regarding antiviral treatment.
2. Pre-therapeutic assessment
Chronic HBV infection is not necessarily accompanied by progressive liver disease requiring
antiviral therapy. Therefore, as a first step, an accurate evaluation of all HBsAg-positive
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carriers is required in order to identify: a) the phase of infection, b) the subjects with chronic
liver damage, c) the stage of liver disease, d) the concurrent causes of liver disease, and e)
patients requiring treatment.
The natural history of chronic HBV infection can be divided into five, not necessarily sequential,
phases (Figure 1). Firstly, the (i) immune-tolerant phase is characterized by high levels of serum
HBV DNA, HBeAg positivity, normal ALT levels, and mild or absent liver necroinflammation.
In patients who remain in the immune-tolerant phase, disease progression is minimal [3]. After
a variable time depending on the age at acquisition of HBV infection, immune-tolerance to the
virus is lost and the immune system mounts an attack on the infected hepatocytes, thus entering
into the (ii) immune-reactive phase.This phase is characterized by fluctuating, but progressively
decreasing, HBV-DNA levels, elevated ALT and hepatic necroinflammation (HBeAg-positive
CHB). A prolonged immune-reactive phase with multiple ALT flares may result in progressive
liver fibrosis, leading to cirrhosis. An important outcome of the immune-reactive phase is the se‐
roconversion from HBeAg to anti-HBe, thus marking the transition to the (iii) immune-control
phase, characterized by low (<2000 IU/ml) or undetectable serum HBV DNA, normal ALT levels,
and disappearance of liver necroinflammation (inactive carrier state). The estimated annual inci‐
dence of spontaneous HBeAg seroconversion is 2%-15%, depending on factors such as age, ALT
levels, and HBV genotype [2]. In a minority of patients, despite HBe seroconversion, reactiva‐
tion of HBV replication may occur due to the selection of HBeAg defective HBV mutants. This
(iv) reactivation phase is characterized by positivity for anti-HBe antibodies, fluctuating HBV
DNA and ALT levels and a high risk of progression to severe hepatic fibrosis (HBeAg-negative
CHB). In patients with periodic ALT flares and normalization, HBV-DNA levels can fall below
the inactive carrier cut-off (2000 IU/ml), making differential diagnosis between active CHB and
the inactive carrier status problematic. Therefore, to warrant an accurate differential diagnosis,
it is mandatory to monitor serum HBV-DNA by sensitive and quantitative polymerase chain re‐
action (PCR) assays and ALT levels over a period of at least 1 year. A recent study, however,
demonstrated that a single-point combined quantification of HBV-DNA (<2000 IU/ml) and
HBsAg (<1000 IU/mL) permits to identify inactive HBV genotype D carriers with a very high di‐
agnostic accuracy which is comparable to that of 1-year monthly monitoring [4]. In the (V)
“HBsAg-negative phase” after HBsAg loss, low-level HBV replication may persist with detecta‐
ble HBV DNA in the liver [5]. In patients with “occult” HBV infection the persistence of an effi‐
cient HBV immunological control has been demonstrated [6], and it is now well known that
immunosuppression may lead to HBV reactivation in these patients.
On the basis of the serological and virological profile, three distinct HBsAg carrier types can
be identified, each characterized by a distinct natural course, prognosis, and treatment indi‐
cations: 1) immune tolerant carrier, 2) inactive carrier, 3) carrier with CHB (HBeAg-positive
and HBeAg-negative CHB). In both tolerant and inactive HBV carriers, treatment is not indi‐
cated, but an appropriate longitudinal follow-up is crucial. Immunotolerant patients should
be subjected to ALT measurements every 3-6 months and should be tested for the presence
of HBeAg every 6 months. In the inactive carriers, ALT and HBV DNA levels should be as‐
sessed every 3 months during the first year, and then every 6 months [7-9]. Patients with
serum HBV DNA <2000 IU/ml and levels of HBsAg less than 1000 IU/ml, may require less
frequent monitoring due to a very low probability of disease reactivation [7].
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Figure 1. Natural history of chronic HBV infection
In the HBsAg carriers with CHB, the diagnostic work-up must be continued and the severity
of liver disease should be assessed by laboratory tests, and hepatic ultrasound examination.
A liver biopsy would be useful for determining the grade of necroinflammation and stage of
fibrosis. Prognosis and management of CHB greatly depend on the stage and progression of
liver fibrosis and thus the risk of developing cirrhosis. In addition, liver biopsy may help to
clarify diagnosis when ALT and HBV DNA levels are discordant and to exclude other
coexistent causes of liver disease (e.g. fatty liver or alcoholic liver disease).
Liver biopsy has traditionally been considered the “gold standard” to measure fibrosis. How‐
ever, liver biopsy is an invasive procedure which can be painful, and carries a small risk of com‐
plications; it is also costly and prone to sampling errors. To provide a reliable estimation of
grading and staging of liver disease, liver biopsy specimens should be at least 20-25 mm long
and/or containing more than 11 complete portal tracts [10]. Recently, non-invasive methods,
including serum markers and transient elastography, are being increasingly utilized to assess
liver fibrosis [10]. Transient elastography (FibroScan) is a rapid, noninvasive, and reproducible
method for measuring liver stiffness, which correlates with the degree of liver fibrosis. It has
demonstrated a high diagnostic accuracy for the detection of cirrhosis, but transient elastogra‐
phy might be inaccurate in discriminating between the different stages of intermediate fibrosis
(F1 vs F2), F2 being considered the threshold for initiating antiviral therapy. Moreover, stiff‐
ness measurement may be influenced by potential confounding factors such as additional
space-occupying tissue abnormalities (e.g. oedema and inflammation, cholestasis).
Lastly, in the diagnostic work-up of CHB, the presence of other possible liver damaging
cofactors (co-infections with HDV, HCV and HIV, co-morbidities including alcoholism,
autoimmune or metabolic liver disease) which would increase the risk of progression to
cirrhosis or HCC should be assessed [11].
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3. Treatment indications
Candidates for treatment are the HBsAg carriers with CHB and, consequently, those with
active viral replication, increased ALT levels and evidence of liver disease at liver biopsy or
other non-invasive methods.
According to the 2012 HBV guidelines of the European Association for the Study of the Liver
(EASL), patients should be considered for treatment when they present HBV DNA levels above
2000 IU/ml, serum ALT levels above the upper limit of normal (ULN) and a liver biopsy
showing moderate to severe necroinflammation and/or at least moderate fibrosis using a
standardized score system. The comparison between EASL guidelines and American Associ‐
ation for the Study of Liver Diseases (AASLD) guidelines and Asian Pacific Association for
the Study of the Liver (APASL) guidelines can be found in Table 1.
However, patients with compensated or decompensated cirrhosis and detectable HBV DNA
should be considered for treatment, independent of ALT levels. Moreover, treatment indica‐
tions should also take into account the patient’s age, health status, family history of HCC or
cirrhosis and extrahepatic manifestations.
                                 
                                     
                               
                                   
               
Criteria EASL 2012(Ref.7) AASLD 2009(Ref.8) APASL 2008(Ref.9)
HBV DNA treatment 
threshold
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- HBeAg(-) (IU/mL)
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Table 1. EASL guidelines compared to other international guidelines
4. Goal of therapy and end-points
The ultimate goal of CHB therapy is the prevention of cirrhosis, hepatic decompensation and/
or HCC [7-9]. This goal can be achieved if HBV replication can be suppressed in a sustained
manner, thus leading to biochemical remission, HBe seroconversion in HBeAg-positive
patients, histological improvement and prevention of cirrhosis and its complications. Several
studies have demonstrated that undetectable or low levels of HBV DNA are associated with
a lower risk to develop cirrhosis [12-14].
Loss of HBsAg from serum with or without seroconversion to anti-HBs is considered the ideal
end-point of therapy, as it is associated with remission of chronic hepatitis B activity and an im‐
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proved long-term outcome [11]. The loss of HBsAg, however, is infrequently achieved with
currently available anti-HBV agents. Hence, a more realistic end-point is the induction of a sus‐
tained or maintained virological response. It must be emphasized that a complete eradication
of HBV infection is impossible to achieve due to the persistence of the so-called covalently-
closed-circular DNA (cccDNA), the transcriptionally active HBV mini-cromosome in the nu‐
cleus of infected hepatocytes; that is to say, that an HBV infected patient can be “cured” but the
HBV infection cannot be eradicated and continues to persist as an occult infection.
5. Anti-HBV drugs
Two different types of drugs have been approved for the treatment of CHB: convention‐
al  interferon alpha (IFN) and its  pegylated form (Peg-IFN),  and 5 nucleoside/nucleotide
analogues  (NAs)  (Figure  2).  Currently,  IFN  has  been  replaced  by  Peg-IFN  due  to  the
more  convenient  administration  (once  weekly).  There  are  two  pegylated-IFN  formula‐
tions: Peg-IFN alpha-2a and Peg-IFN alpha-2b which have shown similar efficacy in clin‐
ical  trials,  but only the former is  globally licensed for treatment of CHB, while Peg-IFN
alpha-2b  has  been  approved in  only  a  few countries.  Among the  nucleoside  analogues
with anti-HBV activity,  emtricitabine is not licensed for HBV treatment in most Europe‐
an countries and its combination with tenofovir in one tablet (Truvada) has been licensed
only for treatment of human HIV infection.
Approved drugs
Interferons
Nucleoside/nucleotide
analogues
Chronic Hepatitis B
 Conventional IFN‐α
 Peg‐IFN α‐2a (Pegasys)
 Lamivudine (Zeffix)
• Adefovir (Hepsera) 
 Entecavir (Baraclude)
 Telbivudine (Sebivo)
 Tenofovir (Viread)
Combined antiviral and 
immunomodulatory effect Direct antiviral effect
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Figure 2. Approved drugs for therapy of chronic hepatitis B
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6. Peg-interferon
Peg-IFN is a cytochine with a dual antiviral and immunomodulatory activity and is adminis‐
tered by subcutaneous injections. After binding with receptors located on the surface of several
different cells, it induces the activation of at least 40 cellular genes, encoding for several antiviral
proteins. Peg-IFN suppresses HBV virion budding, HBV entry and synthesis of the nucleocap‐
sid; moreover, this cytochine enhances the interaction between the antigen-presenting cells and
CD4, and between CD8 and infected hepatocytes. Therefore, Peg-IFN has the potential for an
immune-mediated control of HBV infection, thus providing the opportunity to obtain a sus‐
tained virological response after treatment discontinuation, and the possibility of inducing
HBsAg loss in patients who achieve and maintain undetectable HBV DNA. IFN-based treat‐
ment, however, is often complicated by the occurrence of side effects, such as influenza-like
symptoms, fatigue, neutropenia, thrombocytopenia, and depression, which sometimes require
dose modification and cause premature cessation of treatment [15]. Moreover, Peg-IFN is con‐
traindicated in patients with decompensated HBV-related cirrhosis or autoimmune disease, in
patients with uncontrolled severe depression or psychosis, in patients receiving immunosup‐
pressive therapy or chemotherapy, and in female patients during pregnancy [7].
7. Nucleoside/nucleotide analogues
NAs are oral direct antiviral agents which specifically inhibit the viral polymerase/reverse
transcriptase, an enzyme with a crucial role in the HBV life cycle. As a result, NAs block the
production of new virions and progressively reduce serum HBV DNA to undetectable levels,
but they have little or no effect on the cccDNA present in the nucleous of the infected hepato‐
cytes. The persistence of the intrahepatic cccDNA determines the reactivation of HBV repli‐
cation after stopping NA treatment and therefore justifies the need for a long-term (potentially
life-long) therapy for a sustained viral replication control.
After lamivudine (LAM), the first nucleoside analogue approved for the treatment of CHB,
another two nucleosides, telbivudine (LdT) and entecavir (ETV), and two nucleotide ana‐
logues, adefovir (ADV) and tenofovir (TDF) have become gradually available in recent years.
NAs are characterized by a different antiviral potency and drug-resistance pattern. Entecavir
and tenofovir are the two most potent analogues with a high barrier to resistance development.
Resistance rates in NA-naïve patients treated with monotherapy are shown in Figure 3.
The main advantages and disadvantages of Peg-IFN and NAs in the treatment of CHB are
shown in the following Table 2.
8. Treatment strategies
There are two different therapeutic strategies for both HBeAg-positive and HBeAg-negative
CHB patients: short-term or “curative” treatment and long-term or “suppressive” treatment
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(Figure 4). The first strategy aims to obtain a sustained suppression of viral replication off-
treatment by inducing an immune controll status of HBV infection. The immune control status
corresponds to the profile of an inactive carrier: normal ALT levels coupled with HBV DNA
<2000 IU/ml and anti-HBe positivity. This strategy is IFN-based (Peg-IFN administered for 48
weeks); a finite treatment with NA is possible only in HBeAg-positive patients. The second
strategy aims to obtain a rapid and long-term maintained viral suppression (HBV DNA <10-15
IU/ml). This strategy is exclusively based on NAs.
*Collation of currently available data – not from head‐to‐head studies
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Figure 3. Incidence of Resistance in NA-naïve patients
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• Higher rates of anti-HBe 
& anti-HBs seroconver-
sion with 12 mos of 
therapy 
• Absence of resistance
• Potent antiviral effect
• Good tolerance
• Oral administration
Disadvantages • Moderate antiviral effect
• Inferior tolerability
• Risk of adverse events
• Subcutaneous injections
• Indefinite duration
• Risk of resistance
• Unknown long-term safety
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Table 2. Main advantages and disadvantages of Peg-IFN and Nucleos(t)ides analogues (NAs) in chronic hepatitis B
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years
Long-term “suppressive” treatment
HBV DNA undetectable by PCR (<10-15 IU/ml) 
NA 
HBsAg loss
HBV DNA <2000 IU/ml
ALT < UNL 
(Anti-HBe+)
On treatment 
response
Follow-up IFN  
Short-term “curative” treatment
HBsAg loss
Figure 4. Therapeutic strategies for chronic hepatitis B
9. First-line monotherapy
Peg-IFN, entecavir or tenofovir are recommended as first-line monotherapy by all major
guidelines in patients with CHB or compensated cirrhosis [7-9]. The choice of first-line
monotherapy should be based on several factors including host, virus and drug related factors
(Figure 5). The most favourable candidates for Peg-IFN are those with low HBV DNA levels,
high ALT and HBV genotype A or B rather than C or D, and those without advanced disease.
Peg-IFN alpha-2a is administered as subcutaneous injections at the dose of 180 μg once weekly
for 48 weeks.
Entecavir or tenofovir are the only therapeutic options in patients with decompensated liver
disease, in patients undergoing immunosuppressive treatment, in patients with controindi‐
cations or unwilling to receive Peg-IFN. The licensed entecavir dose for patients with decom‐
pensated cirrhosis is 1 mg (instead of 0.5 mg for patients with CHB or compensated liver
disease) once daily. Tenofovir is administered orally at dosage of 245 mg/die.
For oral antiviral agents, in HBeAg-positive patients, treatment can be discontinued after a 12
month-consolidation therapy from documented HBeAg seroconversion with undetectable
HBV DNA. Close monitoring for relapse is required following therapy discontinuation. In
HBeAg-negative patients, long-term treatment is necessary and can be stopped when con‐
firmed HBsAg loss occurs [7,8].
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As Peg-IFN can achieve a sustained off-therapy response in only a minority of cases, and
a  proportion  of  patients  cannot  tolerate  or  present  controindications  to  IFN  or  do  not
wish to  be treated with Peg-IFN,  long-term treatment  with NAs is  the  most  commonly
used treatment strategy.
First-line monotherapy
Choice based on:
Host Virus
Drug
• HBeAg status
• HBV DNA levels
• Genotype
• Age
• Stage of fibrosis
• ALT levels
• Comorbidities
• Controindications
• Coinfections
• Patient’s preference
• Compliance 
• Efficacy
• Resistance profile
• Safety profile
• Costs
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Figure 5. Factors influencing the choice of first-line monotherapy
10. Virological and non-virological monitoring
During Peg-IFN therapy, full blood counts and serum ALT levels should be monitored
monthly and TSH should be assessed every 3 months. All patients should be monitored for
safety throughout the 12 months of treatment. Serum HBV DNA levels should be assessed by
real-time PCR at 3, 6, 12 months during treatment and at 6 and 12 months post-treatment.
Quantitative determination of serum HBsAg levels should be checked after 3 months of
therapy in order to identify patients with a low probability of response in whom IFN therapy
discontinuation should be considered [7]. In HBeAg-positive patients, HBeAg and anti-HBe
should be tested every 6 months. Lastly, in all responder patients, HBsAg should be checked
at 12-month intervals [7].
In patients treated with NAs, HBV DNA levels should be monitored at month-3 to ascertain
virological response, and thereafter, every 3-6 months. In patients treated with ETV or TDF,
the frequency of DNA measurements may be decreased once patient compliance and treatment
efficacy are confirmed. In HBeAg-positive patients, HBeAg and anti-HBe should be tested
every 6 months. HBsAg should be checked at intervals of 12 months in all patients with
undetectable HBV DNA by real-time PCR [7].
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All NAs are cleared by the kidneys, therefore all patients should be tested for serum creatinine
levels and estimated creatinine clearance at baseline to identify the need for dose adjustments.
As the nephrotoxic potential damage seems to be higher for nucleotide analogues, it is
recommended for patients treated with ADV or TDF renal monitoring, including serum
phosphate levels every three months during the first year and every 6 months thereafter. In
patients at high renal risk or in those who develop clearance creatinine <60 ml/min or serum
phosphate <2 mg/dl, a closer renal monitoring is required [7].
11. IFN-based therapy: Update
Published data have demonstrated that in patients with HBeAg-positive CHB, Peg-IFN ach‐
ieves a more than 30% HBeAg seroconversion rate after one year of treatment [7]. In a registra‐
tion trial,  Peg-IFN alpha-2a provided a sustained immune control which increased post-
therapy; in fact, the HBeAg seroconversion rate continued to increase from 27% at the end of
treatment to 32% during the six months after discontinuing treatment, and to 42% after 1 year
post-treatment [16,17]. Moreover, the seroconversion remained stable over time in >80% of Peg-
IFN alpha-2b treated patients achieving this end-point at the end of therapy [18]. Peg-IFN also
determined HBsAg seroconversion in up to 30% of patients with a long-term follow-up [19].
In patients with HBeAg-negative CHB, Peg-IFN alpha-2a demonstrated a sustained immune
control (HBV DNA <2000 IU/ml) in 31% of patients after 1-year post-treatment. Among these,
88% maintained this response up to 5-year follow-up, and remarkably 28% achieved HBsAg
clearance after 5-years post-treatment [20].
Thus, Peg-IFN treatment remains an attractive therapeutic option, since it provides higher rates
of off-therapy immune control, including HBsAg clearance, when compared with NAs. Howev‐
er, IFN is effective in only a minority of patients (20-30%), has a poor tolerability and significant
costs. Therefore, the improvement of Peg-IFN efficacy is a major challenge. Several attempts
have been made to optimize the cost-effectiveness of IFN-based therapy, including combination
therapy, duration of therapy, pre-treatment predictors of response, and on-treatment predictors
of response. De novo combination therapy with NAs, did not improve sustained response in ei‐
ther HBeAg-positive or HBeAg-negative patients [16,21-23]. Regarding duration of therapy, the
NEPTUNE study conducted in patients with HBeAg-positive CHB reported that dose and dura‐
tion are important because the highest sustained response was obtained with 180 μg and 48
weeks compared to 90 μg and 24 weeks [24]. A recent study has demonstrated that extended
treatment with Peg-IFN alpha-2a to 96 weeks was well-tolerated and improved the rates of sus‐
tained virological response (29% vs 12%) in HBeAg-negative genotype D patients when com‐
pared to the current standard of care of 48 weeks. In addition, after 1-year post-treatment, HBsAg
clearance (6%) was observed only in the extended therapy group [25].
There have been many attempts to identify pretreatment predictors of response, resulting in
the identification of high ALT levels, low HBV DNA, and virus genotype as significant
predictors [7-9]. When combining data from the two largest clinical trials regarding HBeAg-
positive CHB patients [16,26], Buster et al. found that the best candidates for a sustained
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response to Peg-IFN were genotype A patients with high levels of ALT (ALT≥2xULN) or low
levels of HBV DNA (<9 log10 copies/ml), and genotypes B and C patients who have both high
levels of ALT and low HBV DNA. Genotype D patients have a low chance of sustained
response [19]. However, these factors cannot accurately predict response at the individual
level; furthermore, ALT and HBV DNA levels are time-dependent and thus their use in clinical
practice is difficult.
To obtain additional insight into the individual patient’s probability of achieving response to
Peg-IFN, the presence of precore and basal core promoter mutants before treatment has been
correlated to the serological and virological response in HBeAg-positive CHB patients [27].
Data from this study demonstrated that the presence of a wild-type virus at baseline was an
independent predictor of response to Peg-IFN and can assist in improving patient selection
for this treatment option [27]. Lastly, the role of IL28B polymorphisms, clearly indicated as a
baseline host factor predictor of response in patients with chronic hepatitis C, has been also
investigated in CHB patients. Studies in HBeAg-positive patients provided conflicting results,
while, in the only study carried out in HBeAg-negative genotype D patients, the rs12979860
genotype in the IL28B locus independently predicted both virological and serological respons‐
es [28-31]. Therefore, further studies are necessary to define the role of IL28B polymorphisms
as a baseline factor to improve pretreatment patient selection.
A promising approach to improve the cost-effectiveness of Peg-IFN therapy is a response-
guided treatment, based on HBsAg kinetics which permit early identification of either
responders, for whom continuation of treatment to week 48 could be beneficial, or non-
responders who should discontinue IFN treatment.
Two stopping rules at week 12 have been proposed for HBeAg-positive patients: 1) no HBsAg
decline, 2) HBsAg levels >20 000 IU/ml [24,32,33]. The negative predictive value (NPV) for a
sustained response ranged from 82% to 100%, depending on prevalence of HBV genotypes in
the various studies. In HBeAg-negative genotype D patients, no HBsAg decline and <2 log
copies/ml HBV DNA decline at week 12 has been proposed as a stopping rule and independ‐
ently validated with a 100% NPV [34,35]. Overall, therapy with Peg-IFN could be discontinued
at week 12 in the 20% of primary non-responders, who are therefore candidates for suppressive
therapy with NAs.
12. NA-based therapy: Update
Entecavir and tenofovir are the third-generation NAs recommended as first line therapy for
CHB NA-naïve patients by all international guidelines. In registration trials, both antivirals
demonstrated a long-lasting efficacy (viral suppression in more than 95% of patients over 5
years) associated with prevention of developing cirrhosis and to a greater extent, with fibrosis re‐
gression [36-40]. Moreover, these studies reported a minimal risk of drug resistance (1.2% with
ETV after six years and 0% with TDF after 5 years) and a favourable safety profile [39-43]. How‐
ever, as registration trials are conducted under standardized conditions in well-selected and
compliant patients, long-term efficacy and safety of ETV and TDF remain to be confirmed in real-
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life patients who generally have a more complex clinical profile as they are usually older with a
higher prevalence of cirrhosis and comorbidities treated with several concomitant medications.
13. Entecavir in real-life practice
Currently, 2,736 CHB naïve patients have been treated with ETV monotherapy in six real-life
studies and 4-year efficacy and safety data are available for two of these. In a multicenter Italian
study, 418 consecutive NA-naïve patients initiating treatment with ETV 0.5 mg/die were
enrolled. In this cohort, at baseline patients were older (median age 58 years), were predomi‐
nately infected with HBV genotype D (90%), presented a diagnosis of cirrhosis in 49% and
concomitant disease in 56%. Viral suppression was achieved in 100% of patients over 48
months of therapy, independent of HBeAg status. Only one patient with a partial virological
response at week 48 developed resistance at year 3 of treatment with a cumulative rate of 0.2%.
In HBeAg-positive patients, the 4-year cumulative probability of HBeAg seroconversion and
HBsAg loss were 56% and 21%, respectively. However, despite persistent suppression of viral
replication, HCC developed in cirrhotic patients at 2.5% yearly rates, making continuous
surveillance for liver cancer mandatory [44].
A cohort from Hong Kong included 222 NA-naïve patients who demonstrated a 96% 4-year
cumulative rate of virological response [45]. Only one patient developed resistance, corre‐
sponding to a 0.6% cumulative resistance rate up to year-4.
The safety profile of ETV in real-life studies has been excellent, as there have been no reports
of drug-related adverse reactions, discontinuation, or renal toxicity [44-46].
In the VIRGIL multicenter study including 243 consecutive NA-naïve patients receiving ETV
monotherapy, the cumulative probability of achieving a virological response at week 144 was
90% in HBeAg-positive patients and 99% in HBeAg-negative patients [47]. In this cohort, 81%
of patients with partial virological response at 48 weeks reached a virological response during
prolonged ETV monotherapy and no patient developed ETV resistance. When stratifying
patients according to their viral load at week 48, 95% of patients with HBV DNA<1000 IU/ml
and 57% of patients with HBV DNA>1000 IU/ml achieved a virological response without
treatment adaptation during the prolonged treatment period beyond week 48. Therefore, the
authors concluded that no treatment adaptation is needed in the majority of NA-naïve patients
treated with ETV and obtaining partial virological response, particularly in those with HBV
DNA <1000 IU/mL at week 48. In addition, data from the Virgil cohort demonstrated that in
cirrhotic patients, virological response to ETV is associated with a lower probability of
developing a clinical event and disease progression [48].
14. Tenofovir in real-life practice
A total of 1,203 CHB patients, including both NA-naïve and experienced, were treated with
TDF monotherapy in real-life. In the multicenter European cohort study, 302 consecutive NA-
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naïve patients receiving tenofovir (245mg/die) were retrospectively and prospectively
followed for a median period of 28 months. At baseline, median age was 55 years, 35% of
patients had cirrhosis, and concomitant diseases were present in 43% [49]. By month 36,
virological response was reached in 86% of HBeAg-positive patients and 98% of HBeAg-
negative patients. No patient developed drug resistance and, in HBeAg-positive patients,
cumulative probability of HBeAg seroconversion at 30 month was 33%. Most partial virolog‐
ical responders at week 48 achieved undetectable HBV DNA during additional treatment. Data
from this European cohort confirmed the safety profile of TDF reported in the registration
studies. Discontinuation therapy was reported in 9 patients (3%) including renal-related
adverse events in two. The TDF dose was reduced in ten patients (3%) because of a decline in
the estimated glomerular filtration rate [49].
15. Antiviral treatment failure
All patients receiving NA-therapy for CHB should be closely monitored for virologic response
defined as undetectable HBV DNA by a sensitive PCR assay. Failure of antiviral therapy may
be due to several reasons and three types of treatment failure can be identified: 1) Primary Non
Response; 2) Partial Virologic Response; 3) Virologic Breakthrough [50] (Figure 6).
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Figure 6. Antiviral treatment failure in patients receiving NA-therapy
Primary non response is defined as less than 1 log10 IU/ml decrease in HBV DNA level from
baseline after 3 months of therapy; the cause might be attributed to lack of compliance or to
reduced drug susceptibility in a particular individual. Primary non response seems to be more
frequent with Adefovir than with other NAs because of sub-optimal antiviral efficacy. When
a primary non response is identified antiviral treatment should be modified to prevent disease
progression and drug resistant development. In a compliant patient HBV genotyping for the
identification of possible resistant mutations should be performed and a switch to a more
potent NA is recommended [7].
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Partial virological response is defined as a decrease in HBV DNA of more than 1 log10 IU/ml, but
detectable HBV DNA after 24 weeks of therapy in compliant patients treated with low genetic
barrier NAs (LAM, LdT) and after 48 weeks in patients receiving ADV.
Several studies demonstrated that in patients with persisting viremia after 24 weeks of LAM
therapy or 48 weeks of ADV therapy, there is a greater risk of resistance development with
further treatment, compared to patients with undetectable HBV DNA. Therefore, an alterna‐
tive treatment should be considered in these patients before emergence of genotypic resistance
and a change to a more potent drug (entecavir or tenofovir) without cross-resistance is
recommended [7]. With the more potent and high genetic barrier drugs, such as ETV and TDF,
it has been shown that the rate of viral suppression continues to increase even after one year
of treatment, without evidence of drug-resistance [7]. These data suggest that a modification
of therapy is not necessary in patients with partial virological response under entecavir or
tenofovir, especially in those with declining serum HBV DNA levels. However, in patients
with persisting low viremia or when HBV DNA levels do not continue to decline, treatment
should be adapted (switching or adding the other drug) in order to maximize viral suppression
and prevent long-term resistance [7].
Virological  breakthrough  is  defined  as  a  confirmed  increase  in  HBV  DNA  level  of  more
than 1 log10 IU/ml compared to the lowest value (nadir) achieved during treatment. In all
patients  with  a  virological  breakthrough,  treatment  compliance  should  be  assessed.  In
compliant  patients,  virological  breakthrough is  related to  the  selection of  HBV drug-re‐
sistant mutants [50].
16. Antiviral drug-resistance
Antiviral drug-resistance is defined as the reduced susceptibility of a virus to the inhibitory
effect of a drug due to adaptive mutations selected under the selective pressure of antiviral
therapy. In CHB patients treated with NAs, antiviral drug-resistance is due to mutations within
the Polymerase gene of HBV, thus resulting in amino acid substitutions within the polymerase/
reverse transcriptase, target of all NAs. These amino acid changes reduce the affinity of the
enzyme for the antiviral drug, in favor of natural substrates. Moreover, the resistance-
associated mutations selected by a particular NA confer at least some degree of cross-resistance
to other members of its structural group but may also diminish the sensitivity to NAs from a
different chemical group, thus limiting future treatment options (Figure 7).
Development of antiviral drug-resistance is a complex and multistep phenomenon. Figure 8
shows the chronology of events.
Initially, during antiviral therapy, there is the emergence of mutants containing the primary
mutations which are known to confer resistance to the antiviral drug (genotypic resistance).
If treatment is continued, resistant mutants are selected under the selective pressure of the
drug, and over time become the dominant viral species, producing the progressive increase in
serum HBV DNA levels. The virological breakthrough is then followed by a biochemical
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breakthrough, defined as elevation in serum alanine aminotransferase, after achieving
normalization. The time span between virological and biochemical breakthrough may vary
from weeks to years.
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Figure 7. Cross-resistance data for the most frequent resistant HBV variants
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Figure 8. Chronology of events in patients developing antiviral drug-resistance
Development of antiviral drug-resistance has important clinical implications, as it provokes
the loss of clinical benefits due to treatment. The selection of drug-resistant mutants was one
of the most important concerns with the first and second generation NAs, especially with LAM
(Figure 3). Currently, the availability of most potent antivirals with a high barrier to resistance,
such as entecavir and tenofovir, significantly reduced the rates of resistance. Consequently,
the correct choice of a first-line monotherapy provides the best chance of preventing treatment
failure and drug resistance.
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In clinical practice, the early identification of the virologic breakthrough permits an effec‐
tive  timely  rescue  therapy,  before  the  biochemical  breakthrough,  thus  avoiding  disease
progression,  decompensation  in  patients  with  advanced  cirrhosis,  and  accumulation  of
secondary  mutations  which  may  improve  viral  fitness  and  may  become  the  basis  for
cross-resistance with other NAs.
In all patients with a virological breakthrough, genotypic resistance testing should be per‐
formed to confirm genotypic resistance and to determine the pattern of mutations. There are
two commercially available methods for detection of resistance mutations: a direct PCR-based
sequencing, which detects all mutations present in a resistant mutant if it is present in ≥20%
of the viral quasispecies, and a hybridization-based genotyping method, which can detect only
known nucleotide mutations, but is more sensitive, allowing for detection of mutants when
they constitute 5% or more of the total viral population.
The management of treatment failure has changed significantly in recent years, due to the
availability of potent antivirals. An appropriate rescue therapy should be initiated with the
most effective antiviral drug without cross-resistance to reduce the risk of selecting multiple
drug-resistant viral strains. The add-on strategy is the therapeutic approach recommended by
guidelines, in order to prevent the emergence of multi-drug resistant strains and raise the
resistance barrier. However, with the availability of more potent drugs, such as entecavir and
tenofovir, there is a trend to recommend a switch to a complementary drug having a high
barrier to resistance. Both options are considered in the recent EASL guidelines [7]. Recom‐
mendations for treatment adaptation in CHB-resistant patients are showed in Table 3. The
switch strategy does not apply to patients who have been exposed to multiple monotherapies;
these patients should be treated with add-on strategies in order to minimize the risk of
subsequent treatment failure.
Resistance Action
LAM resistance Switch to TDF (add ADV if TDF not available)
ADV resistance
If patient was NA naive before ADV: Switch to ETV or TDF; 
ETV may be preferred in such patients with high viraemia
If patient had prior LAM resistance: Switch to TDF and 
add a nucleoside analogue
LdT resistance Switch to or add TDF (add ADV if TDF not available)
ETV resistance Switch to or add TDF (add ADV if TDF not available)
TDF resistance
TDF resistance not detected to date: add a nucleoside 
analogue Switch to ETV if patient had no prior LAM 
resistance 
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Table 3. EASL 2012 Guidelines recommendations in patients with antiviral resistance
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17. Summary and conclusions
Chronic hepatitis B remains a serious clinical problem because of its worldwide distribution
and potential progression of liver damage. Over the last decades, treatment of CHB has greatly
advanced due to the availability of safe and effective drugs and guidelines have been devel‐
oped. Both Peg-IFN and two NAs, entecavir and tenofovir, can currently be indicated as first-
line therapies for CHB.
Peg-IFN  treatment  is  a  short-term  treatment  strategy  which  provides  a  significant  off-
treatment  sustained  responses,  including  loss  of  HBsAg.  However,  as  Peg-IFN is  effec‐
tive  in  20-30% of  patients,  it  should,  therefore,  be  considered only  for  patients  with  an
elevated possibility of response based on pre-treatment and on-treatment factors. In par‐
ticular quantitative HBV-DNA and HBsAg may be suitable to early identify patients who
are unlikely to benefit from Peg-IFN early during the treatment course, thereby avoiding
unnecessary treatment. Nevertheless, despite this individualised and response-guided ap‐
proach, increasing the cost-effectiveness of Peg-IFN therapy remains a clinical challenge.
Combining Peg-IFN with NA appears to be the most appealing approach to increase the
efficacy  of  antiviral  therapy  and  new  trials  on  a  combination  of  Peg-IFN  with  ETV  or
TDF are required.
Currently,  nucleos(t)ides  analogues  represent  the  treatment  option  used in  the  majority
of  CHB patients  due to  their  potent  antiviral  effect,  oral  administration (one oral  tablet
daily) and optimum tolerance. In registration trials, entecavir and tenofovir, third-genera‐
tion potent antivirals with a high barrier to resistance, showed long-term HBV-DNA sup‐
pression,  low  rise  of  resistance,  potential  reversion  of  fibrosis  and  no  progression  to
cirrhosis,  and lower risk of  adverse clinical  events  in cirrhotic  patients,  except  for  HCC
development. Real life studies have confirmed the long-term efficacy and safety of these
two first-line NAs. However, NAs require a long-term, perhaps indefinite, treatment thus
raising  several  concerns:  patient’s  commitment  to  lifelong  treatment,  adherence,  long-
term  safety,  drug  resistance  in  the  long-term  and  costs.  Combination  of  IFN  and  NAs
might  achieve  an  antiviral  synergy  and  provide  new  opportunities  to  increase  HBsAg
clearance  rates  and  shorten  treatment  duration.  New  studies  exploring  different  strat‐
egies of combining Peg-IFN with ETV or TDF are required to further improve the treat‐
ment of chronic hepatitis B.
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